SCHEMBL14133489

SCHEMBL14133489

CC(=O)N1N=C(c2ccc(NS(=O)(=O)c3ccccc3)cc2)CC1c1ccc(N(C)C)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.64
▸ NPC1 O15118 2/20 0.64
▸ RAB9A P51151 2/20 0.64
▸ SMN1; SMN2 Q16637 1/20 0.64
▸ ACHE P22303 2/20 0.57
▸ MEN1 O00255 1/20 0.56
▸ ALDH1A1 P00352 1/20 0.56
▸ LMNA P02545 1/20 0.56
▸ MAPT P10636 1/20 0.56
▸ PKM P14618 1/20 0.56
▸ KMT2A Q03164 1/20 0.56
▸ TDP1 Q9NUW8 1/20 0.56
▸ L3MBTL1 Q9Y468 1/20 0.56
▸ NT5E P21589 1/20 0.55
▸ PTGS2 P35354 3/20 0.54
▸ CA1 P00915 2/20 0.54
▸ CA2 P00918 2/20 0.54
▸ CA9 Q16790 2/20 0.54
▸ CA12 O43570 1/20 0.54
▸ CA4 P22748 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14136237 0.91 NT5E (0.66) KDM4ENPC1RAB9AACHEALDH1A1
SCHEMBL14136259 0.91 PTGS2 (0.67) KDM4ENPC1RAB9ASMN1; SMN2MEN1
SCHEMBL14133994 0.89 ACHE (0.72) KDM4EACHEALDH1A1MAPTPKM
SCHEMBL14133479 0.89 MAOA (0.64) NPC1RAB9AACHENT5EPTGS2
SCHEMBL14133476 0.88 ACHE (0.59) KDM4ENPC1RAB9AACHENT5E
SCHEMBL14133910 0.88 PTGS2 (0.69) NPC1RAB9AACHEMEN1KMT2A
SCHEMBL14133795 0.88 KDM4E (0.80) KDM4ENPC1RAB9ASMN1; SMN2MEN1
SCHEMBL14058690 0.86 NPC1 (0.74) NPC1RAB9AMEN1ALDH1A1MAPT
SCHEMBL14136238 0.85 ACHE (0.69) KDM4ENPC1RAB9AACHEALDH1A1
SCHEMBL14133644 0.85 CA1 (0.64) ACHEALDH1A1PKMPTGS2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012160447-A1 3, 5 -DIPHENYL- SUBSTITUTED PYRAZOLINES FOR THE TREATMENT OF CANCER, PROLIFERATIVE, INFLAMMATORY OR AUTOIMMUNE DISEASES DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — WO disclosed
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — US disclosed
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 PDK2, PDK4, PDK3 KDM4E 376/4885NPC1 3749/4885RAB9A 3384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback